Skip to main content

Table 1 Baseline characteristics of participants by treatment at randomization

From: Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

 

All (n = 51)

Glibenclamide (n = 23)

Acarbose (n = 28)

P value

Gender (female, %)

51.0%

56.5%

46.4%

0.477

Age (years)

53.7 ± 8.2

54.7 ± 8.3

52.8 ± 8.2

0.378

Disease duration (years)

6.9 ± 4.6

6.0 ± 4.7

7.6 ± 4.5

0.106

BMI (kg/m2)

25.6 ± 3.3

25.3 ± 3.8

25.9 ± 3.0

0.334

HbA1c (%)

8.4 ± 1.2

8.6 ± 1.6

8.2 ± 0.8

0.691

Fasting plasma glucose (mmol/l)

8.5 ± 2.3

9.0 ± 3.0

8.2 ± 1.3

0.538

DI30

41.1 ± 25.0

36.8 ± 19.1

44.7 ± 29.0

0.247

DI120

57.3 ± 28.6

51.2 ± 24.2

62.5 ± 31.4

0.289

HOMA-IR

3.7 ± 2.9

4.7 ± 3.9

2.9 ± 1.5

0.316

MISI

3.4 ± 1.8

3.2 ± 1.7

3.6 ± 1.8

0.321

HOMA-β (%)

44.9 ± 40.4

52.3 ± 49.7

38.9 ± 30.4

0.248

Insulinogenic index30 (pmol/mmol)

42.1 ± 63.4

35.0 ± 37.2

47.9 ± 79.0

0.416

  1. Chi-square test. Mann–Whitney U test. Data are presented as mean ± standard deviation or percentage of participants.
  2. DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index; HOMA-IR, homeostasis model assessment insulin resistance index; MISI, Matsuda insulin sensitivity index.